Basal cell carcinoma natural history: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Basal cell carcinoma}} | {{Basal cell carcinoma}} | ||
{{CMG}} | {{CMG}} {{AE}} Saarah T. Alkhairy, M.D. | ||
==Overview== | ==Overview== | ||
==Natural History== | |||
==Complications== | |||
Complications of basal cell carcinoma are the following: | |||
*A risk of reoccurrence | |||
*An increased risk of other types of skin cancer | |||
*Metastasis | |||
*Ovarian calcification or fibroma<ref name="EvansLadusans1993">{{cite journal|last1=Evans|first1=D G|last2=Ladusans|first2=E J|last3=Rimmer|first3=S|last4=Burnell|first4=L D|last5=Thakker|first5=N|last6=Farndon|first6=P A|title=Complications of the naevoid basal cell carcinoma syndrome: results of a population based study.|journal=Journal of Medical Genetics|volume=30|issue=6|year=1993|pages=460–464|issn=1468-6244|doi=10.1136/jmg.30.6.460}}</ref> | |||
*Medulloblastoma<ref name="EvansLadusans1993">{{cite journal|last1=Evans|first1=D G|last2=Ladusans|first2=E J|last3=Rimmer|first3=S|last4=Burnell|first4=L D|last5=Thakker|first5=N|last6=Farndon|first6=P A|title=Complications of the naevoid basal cell carcinoma syndrome: results of a population based study.|journal=Journal of Medical Genetics|volume=30|issue=6|year=1993|pages=460–464|issn=1468-6244|doi=10.1136/jmg.30.6.460}}</ref> | |||
*Cardiac fibroma<ref name="EvansLadusans1993">{{cite journal|last1=Evans|first1=D G|last2=Ladusans|first2=E J|last3=Rimmer|first3=S|last4=Burnell|first4=L D|last5=Thakker|first5=N|last6=Farndon|first6=P A|title=Complications of the naevoid basal cell carcinoma syndrome: results of a population based study.|journal=Journal of Medical Genetics|volume=30|issue=6|year=1993|pages=460–464|issn=1468-6244|doi=10.1136/jmg.30.6.460}}</ref> | |||
*Cleft palate<ref name="EvansLadusans1993">{{cite journal|last1=Evans|first1=D G|last2=Ladusans|first2=E J|last3=Rimmer|first3=S|last4=Burnell|first4=L D|last5=Thakker|first5=N|last6=Farndon|first6=P A|title=Complications of the naevoid basal cell carcinoma syndrome: results of a population based study.|journal=Journal of Medical Genetics|volume=30|issue=6|year=1993|pages=460–464|issn=1468-6244|doi=10.1136/jmg.30.6.460}}</ref> | |||
*Ophthalmic abnormalities such as squint or cataract<ref name="EvansLadusans1993">{{cite journal|last1=Evans|first1=D G|last2=Ladusans|first2=E J|last3=Rimmer|first3=S|last4=Burnell|first4=L D|last5=Thakker|first5=N|last6=Farndon|first6=P A|title=Complications of the naevoid basal cell carcinoma syndrome: results of a population based study.|journal=Journal of Medical Genetics|volume=30|issue=6|year=1993|pages=460–464|issn=1468-6244|doi=10.1136/jmg.30.6.460}}</ref> | |||
==Prognosis== | ==Prognosis== | ||
Although basal cell carcinoma rarely [[metastasis|metastasizes]], it grows locally with invasion and destruction of local tissues, without stopping. The cancer can impinge on vital structures and result in loss of extension or loss of function or rarely | Although basal cell carcinoma rarely [[metastasis|metastasizes]], it grows locally with invasion and destruction of local tissues, without stopping. The cancer can impinge on vital structures and result in loss of extension or loss of function or rarely death. The vast majority of cases can be successfully treated before serious complications occur. The recurrence rate for the above treatment options ranges from 50% to 1% or less. | ||
In choosing the therapy, one must weigh the benefit gained from the morbidity of the procedure. As most basal cell carcinomas are slow growing, and not deadly; the health and age of the patient must be considered. Although difficult to discuss, radiation therapy, topical chemotherapy, or no treatment at all should be considered in ill or frail individuals in difficult to excise tumor of no immediate harm to the individual. While methods with the highest cure rate should be considered for young and healthy individuals with long life expectancy. | In choosing the therapy, one must weigh the benefit gained from the morbidity of the procedure. As most basal cell carcinomas are slow growing, and not deadly; the health and age of the patient must be considered. Although difficult to discuss, radiation therapy, topical chemotherapy, or no treatment at all should be considered in ill or frail individuals in difficult to excise tumor of no immediate harm to the individual. While methods with the highest cure rate should be considered for young and healthy individuals with long life expectancy. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
| Line 23: | Line 33: | ||
[[Category:Pathology]] | [[Category:Pathology]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
Revision as of 19:01, 27 July 2015
|
Basal cell carcinoma Microchapters |
|
Diagnosis |
|---|
|
Case Studies |
|
Basal cell carcinoma natural history On the Web |
|
American Roentgen Ray Society Images of Basal cell carcinoma natural history |
|
Risk calculators and risk factors for Basal cell carcinoma natural history |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Saarah T. Alkhairy, M.D.
Overview
Natural History
Complications
Complications of basal cell carcinoma are the following:
- A risk of reoccurrence
- An increased risk of other types of skin cancer
- Metastasis
- Ovarian calcification or fibroma[1]
- Medulloblastoma[1]
- Cardiac fibroma[1]
- Cleft palate[1]
- Ophthalmic abnormalities such as squint or cataract[1]
Prognosis
Although basal cell carcinoma rarely metastasizes, it grows locally with invasion and destruction of local tissues, without stopping. The cancer can impinge on vital structures and result in loss of extension or loss of function or rarely death. The vast majority of cases can be successfully treated before serious complications occur. The recurrence rate for the above treatment options ranges from 50% to 1% or less.
In choosing the therapy, one must weigh the benefit gained from the morbidity of the procedure. As most basal cell carcinomas are slow growing, and not deadly; the health and age of the patient must be considered. Although difficult to discuss, radiation therapy, topical chemotherapy, or no treatment at all should be considered in ill or frail individuals in difficult to excise tumor of no immediate harm to the individual. While methods with the highest cure rate should be considered for young and healthy individuals with long life expectancy.